News | Peripheral Artery Disease (PAD) | August 16, 2016

Cardiovascular Systems Releases 30-Day Results from Liberty 360° Study

Data shows high freedom from MAE rates across all Rutherford classes following endovascular interventions, including atherectomy

Cardiovascular Systems Inc., LIBERTY 360 study, Amputation Prevention Symposium, PAD, peripheral artery disease, atherectomy

August 16, 2016 — Cardiovascular Systems Inc. (CSI) released procedural and 30-day results from its LIBERTY 360° study in a late-breaking presentation at the 2016 Amputation Prevention Symposium (AMP), Aug. 10-13 in Chicago.

LIBERTY 360° is a prospective, observational, multi-center clinical study evaluating the clinical and economic outcomes of a variety of endovascular interventions in patients with symptomatic peripheral artery disease (PAD), including critical limb ischemia (CLI), the most severe form of PAD. The study includes all commercially available technologies, including CSI’s Diamondback 360 Peripheral Orbital Atherectomy System (OAS), to treat claudication and CLI. The company completed enrollment of 1,204 patients across 51 sites in the United States in February 2016.

The LIBERTY study includes patients with various levels of PAD ranked on the Rutherford Classification scale. Included in the analysis are 500 Rutherford Class 2-3 patients, 589 Class 4-5 patients and 100 Class 6 patients, those with the most severe form of PAD. The study shows that peripheral interventions can be used successfully across all Rutherford classes, including the most challenging Rutherford Class 6. The majority of devices used were balloons and atherectomy, and the Diamondback OAS was the most frequently used atherectomy device, representing approximately 45 percent of Rutherford Classes 2-5 and over 60 percent of Rutherford Class 6 interventions.

George Adams, M.D., director of Cardiovascular and Peripheral Vascular Research at Rex Hospital in Raleigh, N.C., presented the 30-day results highlighting the freedom from major adverse events (MAE). Additional authors on the abstract are: Jihad Mustapha, M.D., Metro Health Hospital, Mich.; William Gray, M.D., Lankenau Heart Institute, Penn.; Gary Ansel, M.D., Berger Hospital, Ohio; and Michael R. Jaff, M.D., Massachusetts General Hospital.

LIBERTY 30-day outcomes can be seen in the chart below:

 

 

 

Rutherford Class

 

 

 

R2-3

 

 

 

R4-5

 

 

 

R6

Freedom from MAE (30-Day)

 

 

 

99.0%

 

 

 

95.7%

 

 

 

90.7%

Major Amputation

 

 

 

100%

 

 

 

98.8%

 

 

 

95.8%

Target Vessel Revascularization (TVR)

 

 

 

99.4%

 

 

 

96.9%

 

 

 

97.9%

Death

 

 

 

99.6%

 

 

 

99.7%

 

 

 

95.9%

 

Quality of life also improved from baseline across all Rutherford classes.

“The results from the LIBERTY 360° study will provide us with valuable information about the clinical and economic outcomes of atherectomy in PAD patients,” said Adams. “This is the first device study to specifically include patients with a prevalence of calcification across all Rutherford Classes, particularly the most severe form of PAD, Rutherford Class 6. Approximately 50 percent of lesions showed visible calcification on angiography, and we saw a freedom from MAE rate of 90.7 percent for Rutherford Class 6 patients at 30 days. Future data will be essential in identifying the most effective ways to treat this challenging patient population.”

Mustapha said, “Procedural complications rarely resulted in post-procedural hospitalization in all Rutherford Classes and, impressively, 78 percent of Rutherford Class 6 subjects were discharged to their homes.” He concluded, “Early findings in this novel, all-comers PAD study suggest that ‘watchful waiting’ in Rutherford Class 2-3 and ‘primary amputation’ in Rutherford Class 6 may not be necessary. Percutaneous vascular interventions can be successful in these patient populations as well.”

For more information: www.csi360.com 

Related Content

First U.S. Patients Treated With Second-Generation Pantheris Atherectomy Device
News | Atherectomy Devices | July 18, 2018
Avinger Inc. announced in June that several physicians have successfully treated over 40 patients for peripheral artery...
Avinger Receives FDA Clearance of Next-Generation Pantheris Device
Technology | Atherectomy Devices | May 24, 2018
Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug Administration (FDA)...
Medtronic Receives FDA Clearance for Riptide Aspiration System
Technology | Atherectomy Devices | January 16, 2018
Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA)...
Avinger Announces Treatment of First Patients With Next-Generation Pantheris
News | Atherectomy Devices | January 09, 2018
January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St.
Avinger Receives 510(k) Clearance for Pantheris Image-Guided Atherectomy Device Modifications
Technology | Atherectomy Devices | November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices | September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices | May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices | April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
Cardiovascular Systems Inc., CSI, ECLIPSE clinical trial, Diamondback 360 Coronary Orbital Atherectomy System, first subject enrolled
News | Atherectomy Devices | April 04, 2017
Cardiovascular Systems Inc., in partnership with the Cardiovascular Research Foundation (CRF), announced the first...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices | February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Overlay Init